| abstract |
(57) [Summary] [Objective] Extending the half-life in blood of tissue plasminogen activator (tPA) as a thrombolytic agent and improving the decrease in the selectivity of tPA mutein for thrombus, and these thrombolytic agents. Suppress the side effects of. [Structure] Dual specificity for thrombus, one for F, E for the other And tPA lacking the K1 domain, eg tP A bispecific monoclonal antibody against A-6 ', and F, E and K A thrombolytic agent comprising a tPA mutein immunodeficient with one domain deleted. [Effect] A thrombolytic agent having increased thrombolytic ability and selectivity for thrombus, and on the other hand, having low reactivity to fibrinogen and having no side effect such as increased fibrinogen decomposing ability, was obtained. |